+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Avastin (bevacizumab; Genentech/Roche/Chugai) Drug Overview 2019

  • ID: 4462198
  • Drug Pipelines
  • March 2019
  • Region: Global
  • 111 pages
  • Datamonitor Healthcare
Drug Overview
Avastin (bevacizumab; Genentech/Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF). The VEGF protein is an essential component of the angiogenesis pathway, critical for blood vessel formation, facilitating tumor growth, invasion, and metastasis. Inhibiting the VEGF protein leads to decreased blood vessel formation, thereby restricting nutrient intake and limiting tumor growth and development. In the US, Avastin is currently approved for the treatment of renal cell carcinoma, colorectal cancer, non-small cell lung cancer, glioblastoma, cervical cancer, and ovarian cancer.

Analyst Outlook
Avastin (bevacizumab; Genentech/Roche/Chugai) will face significant generic erosion in the US and Europe following patent expiries in 2019 and 2020, respectively. Amgen’s biosimilar Mvasi, which was approved in both the EU and US in 2017 (FDA, 2017; EMA, 2017), is expected to be available for patients immediately upon the expiry of key Avastin patents. While generic erosion is forecast to significantly reduce Avastin’s sales, the drug’s approval for the treatment of renal cell carcinoma (RCC) in Japan will offer some relief, though the size of this market will not be sufficient to offset losses in the US and Europe. Furthermore, the combination of Avastin + Tecentriq (atezolizumab; Roche/Chugai) is in clinical trials for use in the first-line setting. The combination has already provided strong clinical trial data in the Phase III IMmotion 151 study, improving progression-free survival compared to Sutent (sunitinib; Pfizer) in patients whose disease expressed programmed death-ligand 1 (PD-L1).
Note: Product cover images may vary from those shown
OVERVIEW
  • Drug Overview
  • Product Profiles
  • Avastin: Renal cell carcinoma (RCC)
  • Avastin: Non-small cell lung cancer (NSCLC)
  • Avastin: Colorectal cancer (CRC)
  • Avastin: Retinal disorders
  • Avastin: Ovarian cancer
  • Avastin: Breast cancer: triple-negative
  • Avastin: Breast cancer: HR+/HER2-
LIST OF FIGURES
Figure 1: Avastin for RCC – SWOT analysis
Figure 2: The author's drug assessment summary of Avastin for RCC
Figure 3: The author's drug assessment summary of Avastin for RCC
Figure 4: Avastin sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Avastin for non-small cell lung cancer – SWOT analysis
Figure 6: The author's drug assessment summary for Avastin in non-small cell lung cancer
Figure 7: The author's drug assessment summary for Avastin in non-small cell lung cancer
Figure 8: Avastin sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Figure 9: Avastin for colorectal cancer – SWOT analysis
Figure 10: The author's drug assessment summary of Avastin for colorectal cancer
Figure 11: The author's drug assessment summary of Avastin for colorectal cancer
Figure 12: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country, 2016–25
Figure 13: Avastin for retinal disorders – SWOT analysis
Figure 14: The author's drug assessment summary for Avastin in retinal disorders
Figure 15: The author's drug assessment summary for Avastin in retinal disorders
Figure 16: Avastin for ovarian cancer – SWOT analysis
Figure 17: The author's drug assessment of Avastin for ovarian cancer
Figure 18: The author's drug assessment of Avastin for ovarian cancer
Figure 19: Avastin for triple-negative breast cancer – SWOT analysis
Figure 20: The author's drug assessment summary of Avastin for triple-negative breast cancer
Figure 21: The author's drug assessment summary of Avastin for triple-negative breast cancer
Figure 22: Avastin for HR+/HER2- breast cancer – SWOT analysis
Figure 23: The author's drug assessment summary of Avastin in HR+/HER2- breast cancer
Figure 24: The author's drug assessment summary of Avastin in HR+/HER2- breast cancer

LIST OF TABLES
Table 1: Avastin drug profile
Table 2: Avastin Phase III data in RCC
Table 3: Avastin sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 4: Avastin drug profile
Table 5: Avastin pivotal trial data in non-small cell lung cancer
Table 6: Avastin late-phase trial data in non-small cell lung cancer
Table 7: Avastin sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 8: Avastin patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
Table 9: Avastin drug profile
Table 10: Overview of major approvals for Avastin in colorectal cancer
Table 11: Avastin Phase III data in colorectal cancer
Table 12: Avastin sales for colorectal cancer across the US, Japan, and five major EU markets, by country ($m), 2016–25
Table 13: Patients treated with Avastin across the US, Japan, and five major EU markets, by country, 2016–25
Table 14: Avastin drug profile
Table 15: Avastin late-phase trial data in retinal disorders
Table 16: Avastin ongoing late-phase clinical trial in retinal disorders
Table 17: Avastin drug profile
Table 18: Avastin pivotal trial data in ovarian cancer
Table 19: Avastin late-phase trial data in ovarian cancer
Table 20: Avastin ongoing Phase III clinical trials in ovarian cancer
Table 21: Avastin drug profile
Table 22: Avastin pivotal trial data in triple-negative breast cancer
Table 23: Avastin late-phase trial data in triple-negative breast cancer
Table 24: Avastin drug profile
Table 25: Avastin pivotal trial data in HR+/HER2- breast cancer
Table 26: Avastin late-phase trial data in HR+/HER2- breast cancer
Note: Product cover images may vary from those shown
Adroll
adroll